Fulgent Genetics Stock Forecast, Price & News

+0.65 (+0.71 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume748,315 shs
Average Volume1.43 million shs
Market Capitalization$2.69 billion
P/E Ratio6.26
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FLGT News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

Fulgent Genetics logo

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.78 out of 5 stars

Medical Sector

1202nd out of 2,218 stocks

Medical Laboratories Industry

23rd out of 41 stocks

Analyst Opinion: 1.1Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions

Is Fulgent Genetics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Fulgent Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View analyst ratings for Fulgent Genetics
or view top-rated stocks.

What stocks does MarketBeat like better than Fulgent Genetics?

Wall Street analysts have given Fulgent Genetics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fulgent Genetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Fulgent Genetics' next earnings date?

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Fulgent Genetics

How can I listen to Fulgent Genetics' earnings call?

Fulgent Genetics will be holding an earnings conference call on Monday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings data on Thursday, May, 6th. The company reported $6.59 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $5.95 by $0.64. The firm had revenue of $359.43 million for the quarter, compared to analysts' expectations of $326.46 million. Fulgent Genetics had a net margin of 53.91% and a trailing twelve-month return on equity of 101.08%. The business's revenue was up 4536.0% on a year-over-year basis.
View Fulgent Genetics' earnings history

How has Fulgent Genetics' stock been impacted by COVID-19?

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FLGT stock has increased by 821.4% and is now trading at $92.69.
View which stocks have been most impacted by COVID-19

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its second quarter 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $200 million-$200 million, compared to the consensus revenue estimate of $193.95 million.

What price target have analysts set for FLGT?

5 Wall Street analysts have issued 1 year price targets for Fulgent Genetics' shares. Their forecasts range from $40.00 to $140.00. On average, they expect Fulgent Genetics' stock price to reach $88.00 in the next twelve months. This suggests that the stock has a possible downside of 5.1%.
View analysts' price targets for Fulgent Genetics
or view top-rated stocks among Wall Street analysts.

Who are Fulgent Genetics' key executives?

Fulgent Genetics' management team includes the following people:
  • Mr. Ming Hsieh, Chairman, CEO & Pres (Age 65, Pay $248k)
  • Mr. Paul Kim, Chief Financial Officer (Age 54, Pay $253.66k)
  • Mr. Jian Xie, Chief Operating Officer (Age 55, Pay $224.54k)
  • Dr. Han Lin Gao FACMG, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G., Chief Scientific Officer & Laboratory Director (Age 54, Pay $223.51k)
  • Mr. Brandon Perthuis, Chief Commercial Officer
  • Dr. Lawrence M. Weiss M.D., Chief Medical Officer (Age 64)

Who are some of Fulgent Genetics' key competitors?

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Square (SQ), (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (0.05%), State of Alaska Department of Revenue (0.04%) and Inspirion Wealth Advisors LLC (0.01%). Company insiders that own Fulgent Genetics stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends for Fulgent Genetics

Which institutional investors are selling Fulgent Genetics stock?

FLGT stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd.. Company insiders that have sold Fulgent Genetics company stock in the last year include Hanlin Gao, Jian Xie, John C Bolger, and Paul Kim.
View insider buying and selling activity for Fulgent Genetics
or view top insider-selling stocks.

Which institutional investors are buying Fulgent Genetics stock?

FLGT stock was acquired by a variety of institutional investors in the last quarter, including Inspirion Wealth Advisors LLC, and State of Alaska Department of Revenue.
View insider buying and selling activity for Fulgent Genetics
or or view top insider-buying stocks.

How do I buy shares of Fulgent Genetics?

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $92.69.

How much money does Fulgent Genetics make?

Fulgent Genetics has a market capitalization of $2.69 billion and generates $421.71 million in revenue each year. The company earns $214.31 million in net income (profit) each year or $8.85 on an earnings per share basis.

How many employees does Fulgent Genetics have?

Fulgent Genetics employs 700 workers across the globe.

What is Fulgent Genetics' official website?

The official website for Fulgent Genetics is

Where are Fulgent Genetics' headquarters?

Fulgent Genetics is headquartered at 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780.

How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.